Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia von Langabeer, S.E., Haslam, K., Crampe, M., MacDonagh, B., McHugh, J.

Volltext